Rapport Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Good afternoon, everyone. Thank you so much for joining us. Really pleased to have with us the Rapport team. With me, I have Abe Ceesay, Chief Executive Officer, and Troy Ignelzi, Chief Financial Officer.
Questions & Answers
To start here, Abe reports about to initiate its first pivotal program following positive proof-of-concept data in focal onset epilepsy.
In this context, can you lay out the company's key priorities and catalysts over the next 12 to 18 months?
Sure. So thank you, Salveen, for having us here today. So as a reminder, we released our Phase II data in September of '25 and it was phenomenal data. We are very encouraged by that data with RAP-219 and focal onset seizures, that data was really marked by what we saw was pretty much unprecedented results in terms of seizure reduction, roughly a 78%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
